Initiate

Palisade Bio Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 27, 2024
Research, Ulcerative colitis, Exercise, Initiate, Average cost, Patient, Internet, UC, PDE4, Insurance, Trial of the century, IBD, Medicine, Completeness, Inflammatory bowel disease, Therapy, FDA, Autoimmunity, Physician, Consultant, Pharmaceutical industry

Carlsbad, CA, March 27, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company”), a pre-clinical biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the full year 2023 and provided a corporate update.

Key Points: 
  • “2023 was a transformative year for Palisade Bio as we strategically shifted into the autoimmune, inflammatory, and fibrotic disease space, with the focus on our precision medicine approach in inflammatory bowel disease,” commented J.D.
  • “As a result of the progress made by our development team, we are on track to launch the Phase 1 study of PALI-2108 by the end of 2024.
  • Summary of Financial Results for the Year Ended December 31, 2023
    As of December 31, 2023, the Company had cash, cash equivalents and restricted cash of $12.5 million.
  • Net operating loss was $13.1 million for the year ended December 31, 2023 compared to $15.7 million for the year ended December 31, 2022.

Edge Computing: Insights Into Efficiency, Innovation, and Business Value Published by Info-Tech Research Group

Retrieved on: 
Friday, March 15, 2024
Principal, Theft, Organization, Distribution, Initiate, Health, Internet of things, Intermittency, Travel, Research, Human, Infrastructure, Research group, Cryptocurrency

Edge computing is a transformative solution, offering the promise of real-time insights and actions.

Key Points: 
  • Edge computing is a transformative solution, offering the promise of real-time insights and actions.
  • In response to the urgency of addressing these challenges, Info-Tech Research Group has published its latest research blueprint, Initiate Your Edge Computing Journey .
  • Scalability and Distributed Processing: Edge computing supports distributed processing, allowing applications to scale horizontally by adding more edge nodes.
  • Info-Tech Research Group has also opened registration for its upcoming webinar on the potential of edge computing.

Olema Oncology Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Monday, March 11, 2024
Breast cancer, SAN, Cancer, Investigational New Drug, Woman, ESMO, Biomedical Research, FDA, Everolimus, Corporation, Ribociclib, GAAP, SVB, Patient, Clinical trial, Novartis, Congress, Silicon Valley Bank, Oncology, Initiate, IND, Trial of the century, Research, Pharmaceutical industry

“In 2023 we demonstrated the unique opportunity ahead for palazestrant to make a meaningful impact on improving treatment options for women with ER+/HER2- breast cancer.

Key Points: 
  • “In 2023 we demonstrated the unique opportunity ahead for palazestrant to make a meaningful impact on improving treatment options for women with ER+/HER2- breast cancer.
  • Presented palazestrant monotherapy Phase 2 clinical results at the European Society for Medical Oncology (ESMO) Congress 2023 in Madrid, Spain, as an oral presentation demonstrating compelling activity in both wild-type and ESR1-mutant tumor types.
  • Non-GAAP G&A expenses were $3.1 million and $13.3 million for the quarter and year ended December 31, 2023, respectively, excluding $1.4 million and $5.5 million non-cash stock-based compensation expense respectively.
  • A reconciliation of GAAP to non-GAAP financial measures used in this press release can be found at the end of this press release.

DBV Technologies Reports Full Year 2023 Financial Results and Business Update

Retrieved on: 
Thursday, March 7, 2024
Vitesse, European Commission, Marketing, DBV Technologies, Blas, FDA, Form 10-K, File, Research and development, Language, Sale, BLA, Toddler, American College, Form, Financial statement, Safety, American depositary receipt, GAAP, Good news, Immunology, Administration, Net, Food, Asthma, DBV, Initiate, Development, Bank statement, Agreement, Editorial, Cryptocurrency

DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.

Key Points: 
  • DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, today reported financial results for the full year 2023.
  • Published EPITOPE results in the New England Journal of Medicine with an accompanying editorial, entitled, Good News for Toddlers with Peanut Allergy.
  • ET to discuss full year 2023 financial results and provide a business update.
  • The conference call may be accessed by dialing:
    A webcast of the call will also be available under "Events" in the Investors section of the DBV Technologies website: https://dbv-technologies.com/investor-overview/events .

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, February 26, 2024
HER2, PFS, AAAAI, KIT, Research, Completeness, TSS, ASCO, ASH, WT, Cash, Part, Safety, PEAK, AACR, Cogent, Conference, GIST, Society, PPR, Patient, The, PIPE, FGFR2, Clinical trial, Poster, G&A, Sunitinib, Initiate, IND, Brain, TKI, APEX, Cancer, American Academy, Pharmaceutical industry

WALTHAM, Mass. and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.

Key Points: 
  • and BOULDER, Colo., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today provided a business update and reported financial results for the fourth quarter and full year of 2023.
  • SUMMIT is a registration-directed, randomized, double-blind, placebo-controlled, global, multicenter, clinical trial of bezuclastinib in patients with nonadvanced systemic mastocytosis (NonAdvSM).
  • Cash and Cash Equivalents: As of December 31, 2023, Cogent had cash, cash equivalents and marketable securities of $273.2 million.
  • During the quarter Cogent also completed and paid for bulk manufacturing campaigns of bezuclastinib to continue supporting the company’s clinical trials.

Rhythm Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Thursday, February 22, 2024
EMANATE, New Drug Application, Investment, Obesity, BMI, Webcast, Initiate, BBS, Stage 2, Hyperpigmentation, Documentation, Polyphagia, European, GAAP, European Medicines Agency, PCSK1, Type, Type 2, G&A, LG Chem, BV, Completeness, Shanda, Bardet–Biedl syndrome, Clinical trial, LEPR, Medicaid, IND, Prescription, Research, Hunger, Acquisition, Quarter, EMA, MC4R, FDA, Prevalence, PMDA, Patient, POMC, Body mass index, Pharmaceutical industry

-- Acquired global rights to oral MC4R agonist LB54640 from LG Chem --

Key Points: 
  • ET --
    BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2023.
  • Fourth Quarter and Full Year 2023 Financial Results:
    Cash Position: As of December 31, 2023, cash, cash equivalents and short-term investments were approximately $275.8 million, as compared to $333.3 million as of December 31, 2022.
  • S,G&A Expenses: S,G&A expenses were $32.4 million in the fourth quarter of 2023 and $117.5 million for the year ended December 31, 2023, compared to $26.3 million in the fourth quarter of 2022 and $92.0 million for the year ended December 31, 2022.
  • ET today to review its fourth quarter and year end 2023 financial results and recent business activities.

Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates

Retrieved on: 
Thursday, February 22, 2024
Acquisition, PDUFA date, Marketing, Total, Research, Narcolepsy, Share repurchase, FDA, Food, Shanda, Treatment, Research and development, Growth, PDUFA, Generator, Track, Fragile X syndrome, Conference, Prader–Willi syndrome, GAAP, Food and Drug Administration, Administration, Patient, Initiate, Development, Benchmarking, Bank statement

Net product revenue for the quarter ended December 31, 2023 was $168.4 million, compared to $128.3 million for the same period in 2022.

Key Points: 
  • Net product revenue for the quarter ended December 31, 2023 was $168.4 million, compared to $128.3 million for the same period in 2022.
  • The average number of patients on WAKIX increased by approximately 350 sequentially to approximately 6,150 for the quarter ended December 31, 2023.
  • Total Operating Expenses in the fourth quarter of 2023 included one-time Zynerba transaction related costs of $9.8 million.
  • ET
    We are hosting our fourth quarter and full year 2023 financial results conference call and webcast today at 8:30 a.m. Eastern Time.

Cybin Reports Third Quarter Financial Results and Recent Business Highlights

Retrieved on: 
Wednesday, February 14, 2024
Research, Mental Health, FDA, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Well, DMT, PD, Montgomery–Åsberg Depression Rating Scale, Patent, Exercise, Safety, GAD, Indian stock exchange, American College, Patient, Intellectual property, MDD, Initiate, Inc., MADRS, Depression, Pharmaceutical industry

Announced positive Phase 2 topline efficacy and safety data for CYB003, the Company’s proprietary deuterated psilocybin analog, in MDD. The study achieved its primary efficacy endpoint with an impressive mean 14-point difference in Montgomery-Asberg Depression Rating Scale (“MADRS”) score reduction from baseline between CYB003 (12mg) vs. placebo (p=0.0005)1 at three weeks. At six weeks, incremental MADRS score reductions were seen with 79% of patients in remission from depression after just two 12mg doses of CYB003 -- an improvement that is far superior when compared against approved antidepressants and recently reported data with other psychedelics. Based on these encouraging results, and coupled with the fact that CYB003 is being developed as an adjunctive treatment that does not require candidates to discontinue the use of existing antidepressants, the Company intends to commence an international, multisite Phase 3 trial to further evaluate the safety and efficacy of CYB003 capsules in a larger MDD patient population2.

Key Points: 
  • Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic treatment options, today reported unaudited financial results for its third quarter ended December 31, 2023, and recent business highlights.
  • Recent Business and Pipeline Highlights:
    Announced positive Phase 2 topline efficacy and safety data for CYB003, the Company’s proprietary deuterated psilocybin analog, in MDD.
  • Combined Phase 1 results from DMT program support progression to a Phase 2a study in GAD in the first quarter of 20242.
  • Cash-based operating expenses totaled C$17.1 million for the quarter ended December 31, 2023, compared to C$11.1 million, in the prior year quarter.

Palisade Bio Provides Corporate Update and Reiterates Guidance

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Ulcerative colitis, Receipt, Completeness, MHP, Exercise, Internet, Doctor of Pharmacy, PDE4B, UC, Inflammatory bowel disease, Patient, IBD, Initiate, Trial of the century, Pharmaceutical industry

Carlsbad, CA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today provided a corporate update and reiterated upcoming milestones.

Key Points: 
  • “We continue to make significant development progress with PALI-2108, our lead program.
  • The program is providing us with a growing body of data that we find encouraging, including support for a precision medicine approach,” commented J.D.
  • Although smaller, we believe the reconstituted board better matches our stage of development while retaining ethnic and gender diversity.
  • PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by UC.

Modernize Claims Communication for Policyholders with Hi Marley’s New Guidewire Cloud App

Retrieved on: 
Tuesday, February 6, 2024
Software, Mobile, Wireless, Professional Services, Internet, Data Management, Apps, Applications, Technology, Artificial Intelligence, Other Communications, Data Analytics, Insurance, Communications, Telecommunications, Cloud, Initiate, Workflow, Senior, TCPA, AI, Artificial intelligence, P&C, Automation, Communication, Text messaging, SMS

Guidewire (NYSE: GWRE) and Hi Marley announced that Hi Marley’s new Ready for Guidewire validated accelerator is now available to users of ClaimCenter on Guidewire Cloud in the Guidewire Marketplace .

Key Points: 
  • Guidewire (NYSE: GWRE) and Hi Marley announced that Hi Marley’s new Ready for Guidewire validated accelerator is now available to users of ClaimCenter on Guidewire Cloud in the Guidewire Marketplace .
  • Built for the P&C insurance industry, Hi Marley’s Conversational Insurance Cloud platform enables insurers to connect and collaborate with their policyholders via text, mitigating communication inefficiencies.
  • The Insurance Cloud and Guidewire accelerator are enriched with features that leverage artificial intelligence (AI) to ease communication and enhance automation for insurers.
  • “Hi Marley’s technology enables claims professionals to communicate with policyholders via texting - a convenient, preferred communication method for numerous customers.